Processa Pharmaceuticals, Inc. (PCSA)
NASDAQ: PCSA · Real-Time Price · USD
2.610
+0.040 (1.56%)
Aug 10, 2026, 9:53 AM EDT - Market open

Processa Pharmaceuticals Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-14.47-13.99-12.05-11.46-27.53-12.13
Net Income
-14.11-13.56-11.85-11.12-27.42-11.43
Earnings Per Share
-9.40-10.36-96.78-212.00-851.25-375.00
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
1.695.541.194.716.516.5
Total Debt
000.070.150.230.08
Net Cash (Debt)
1.695.541.124.566.2716.42
Net Cash Growth
-40.61%395.34%-75.46%-27.39%-61.79%8.82%
Net Cash Per Share
0.914.239.1386.84194.73535.89

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-12.25-11.39-11.25-8.06-9.61-8.72
Capital Expenditures
---0-0--
Free Cash Flow
-12.25-11.39-11.25-8.07-9.61-8.72
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.